[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-cardiomyopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-cardiomyopathy":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,90,113,141,187,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100289553","mayo-avc-registry-and-biobank-100289553",false,"NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,"ALL",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","RECRUITING","2026-04-22",{"date":44,"type":45},"2026-04-27","ACTUAL",{"date":47,"type":45},"2018-02-09",{"date":49,"type":20},"2027-03",{"name":51,"class":52},"Mayo Clinic","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100528279","phase-3-cmp-mythic-trial-and-registry---cardiomyopathy-with-myocarditis-therapy-with-colchicine-100528279","NCT06158698","CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)","CMP-MYTHiC","Inclusion Criteria Trial and Registry:\n\n* Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides.\n* Patients of 18 years or older\n* Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry.\n* Presence of any of the following characteristics and if symptoms have been present for more than 1 month:\n* Mono-morphic or polymorphic PVC burden of ≥3000 in 24 hours, or NSVTs (defined as \\>3 more consecutive beat lasting \\\u003C30 seconds) or evidence of sustained ventricular tachycardias (SVT).\n* Reduced LVEF on echocardiogram (\\\u003C50%) or on CMRI (\\\u003C60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg\u002FmL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg\u002FmL or more\n* Persistence of increased high-sensitivity troponin levels above the upper reference limit (URL) after at least 2 months from the first assessment and at least a mono-morphic or polymorphic PVC burden of ≥1000 in 24 hours.\n\nExclusion Criteria Registry:\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n\nExclusion Criteria Trial :\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n* Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)\n* Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,\n* Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,\n* Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),\n* Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary\n* Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),\n* Impaired renal function (eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Known history of hepatic cirrhosis or transaminase levels at baseline \\> x3-fold the URL\n* Patients with peripheral eosinophilia (eosinophil count \\>10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization.\n* Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)\n* Women during breastfeeding","18 Years",{"count":64,"type":20},80,"INTERVENTIONAL",[67],"PHASE3","Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.",[25,37,38,70,71],"Heart Failure","Ventricular Arrythmia",[73,74,75,76,77,78,79],"treatment","trial","colchicine","registry","inflammation","outcome","genetic testing","2026-04-15",{"date":82,"type":45},"2026-04-20",{"date":84,"type":45},"2023-11-14",{"date":86,"type":20},"2028-05-02",{"name":88,"class":52},"Niguarda Hospital",10,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":97,"targetDuration":99,"studyType":21,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100585161","creation-of-a-national-multicenter-platform-for-the-study-of-inflammatory-myocardial-disease-pre-myo-cohort-100585161","NCT06898762","Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort","PREMYO","Inclusion Criteria:\n\n• Presence of at least one compatible symptom and at least one objective finding in diagnostic tests (Figure 2), according to the consensus document of the European Society of Cardiology (1):\n\nA. Clinical presentation:\n\n* Acute chest pain: pericardial or pseudo-ischemic.\n* Dyspnea on exertion or at rest for up to 3 months.\n* Dyspnea on exertion or at rest for 3 months - 1 year.\n* Unexplained palpitations \u002F arrhythmias, sudden death recovered.\n* Unexplained cardiogenic shock.\n\nB. Findings in complementary tests:\n\n* ECG: new onset AV block, new onset bundle branch block, ST segment elevation\u002Fdepression, T wave inversion\n* Elevation of TnI\u002FTnT\n* Segmental or global contractility alterations not explained by other causes\n* Positive Lake Louise criteria in cardiac MRI (13) (Annex III Figure S1) • Patients who have given their informed consent.",{"count":98,"type":20},3000,"3 Years","The objectives of this project are: 1) to comprehensively characterize a large national cohort of patients with suspected myocarditis, their clinical phenotype, care management, blood and imaging biomarkers, epidemiological, environmental and genetic data; 2) to retrospectively validate the accuracy of the new hsa-RNA-Chr8:96 biomarker for the diagnosis of myocarditis compared to conventional diagnosis; 3) to identify acquired and inherited mutations, and their interaction with the environment, which explain the susceptibility to myocarditis, its severity and response to treatment; 4) to study the lower incidence in women and the influence of age, considering socio-health and genetic factors.",[102,38],"Myocarditis Acute","2025-03-21",{"date":105,"type":45},"2025-03-27",{"date":107,"type":45},"2023-04-09",{"date":109,"type":20},"2028-12-31",{"name":111,"class":52},"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":65,"phases":124,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":112},"100513110","phase-2-the-effects-of-hydroxychloroquine-in-patients-with-inflammatory-cardiomyopathy-100513110","NCT05961202","The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy","The Efficacy and Mechanism of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy After Myocarditis","HYPIC","Inclusion criteria:\n\n1. Male or female patient aged from 18 to 80 years;\n2. Left ventricular dysfunction \\[left ventricular ejection fraction (LVEF) \\\u003C50%\\] diagnosed by echocardiography (Simpson's biplane) within 30 days before randomization;\n3. Chronic heart failure (lasting \\>6 months) unresponsive to conventional supportive therapy;\n4. High-sensitivity cardiac Troponin I (hs-cTnI) \\>26.2 pg\u002FmL and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) \\>169pg\u002FmL;\n5. Suffered from confirmed fulminant myocarditis in the past;\n6. Diagnosed with chronic inflammatory cardiomyopathy confirmed by myocardial biopsy1;\n7. Absence of cardiotropic viruses at polymerase chain reaction analysis;\n8. Volunteer for the study and written informed consent;\n\nExclusion criteria:\n\n1. Age \\\u003C18 or \\>80 years;\n2. Acute myocardial infarction occurred within the past month;\n3. Subjects who have undergone cardiac surgery or cerebrovascular accidents within 6 months;\n4. Preparing for heart transplantation;\n5. With malignant arrhythmias such as long QT syndrome;\n6. Pregnancy or lactation;\n7. Have participated in any drug clinical trial within the three months;\n8. Presence of contraindications to prednisolone and\u002For hydroxychloroquine (including hypersensitivity to prednisone or hydroxychloroquine, mainly untreated systemic infection, uncontrolled diabetes, poorly controlled endocrine diseases, osteoporosis, gastric or duodenal ulcer, uncontrolled hypertension, leukocytopenia (leukocyte counts \\\u003C 4×109\u002FL), neutropenia (neutrophils \\\u003C 1.5×109\u002FL), thrombocytopenia (platelet levels \\\u003C 130×109\u002FL), anemia (hemoglobin levels \\\u003C 11 g\u002FdL).\n9. Confirmed or possible systemic inflammatory diseases;\n10. On the brink of death or life expectancy of less than 1 year;\n11. Drug or alcohol abuse;\n12. cannot persist in taking medication due to various reasons;\n13. Inability to provide informed consent.","80 Years",{"count":123,"type":20},200,[125,67],"PHASE2","Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study",[38,37],[129,37,130,131],"Inflammatory cardiomyopathy","Hydroxychloroquine","Randomized controlled trial","2024-10-06",{"date":134,"type":45},"2024-10-09",{"date":136,"type":45},"2021-11-01",{"date":138,"type":20},"2025-11-01",{"name":140,"class":52},"Tongji Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":153,"studyType":21,"phases":4,"briefSummary":154,"conditions":155,"keywords":162,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":112},"100561522","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-pediatric-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-myoped-100561522","NCT06591260","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOPED","Inclusion Criteria:\n\n* Written informed consent.\n* Age \\< 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\> 18 years (adults)","0 Years","17 Years",{"count":152,"type":20},20,"30 Years","Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\nOptimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n\nBiomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n\nArrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n\nThe role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n\nUniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[37,156,38,157,158,159,25,160,161],"Ventricular Arrhythmia","Genetic Predisposition","Autoimmunity","Arrhythmia","Immunosuppresion","Catheter Ablation",[37,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177],"Ventricular arrhythmias","Arrhythmias","Arrhythmogenic inflammatory cardiomyopathy","Endomyocardial biopsy","Cardiac magnetic resonance","Ablation","Positron emission tomography","Electroanatomical mapping","Immunosuppressive therapy","Arrhythmic risk stratification","Genetic predisposition","Environment","Implantable cardioverter defibrillator","Implantable loop recorder","Multicenter","2024-09-11",{"date":180,"type":45},"2024-09-19",{"date":182,"type":45},"2013-01-01",{"date":184,"type":20},"2030-12-31",{"name":186,"class":52},"Scientific Institute San Raffaele",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":194,"targetDuration":195,"studyType":21,"phases":4,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":112},"100402555","role-of-endomyocardial-biopsy-and-aetiology-based-treatment-in-patients-with-inflammatory-heart-disease-in-arrhythmic-and-non-arrhythmic-clinical-presentations-an-integrated-approach-for-the-optimal-diagnostic-and-therapeutic-management-100402555","NCT04521790","Role of Endomyocardial Biopsy and Aetiology-based Treatment in Patients With Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management","MYOCAR","Inclusion Criteria:\n\n* Written informed consent.\n* Age ≥ 18 years.\n* Clinically suspected myocarditis.\n* Enrollment performed by one of the participating Centers.\n\nExclusion Criteria:\n\n* Absence of written informed consent.\n* Age \\\u003C 18 years (paediatric population).",{"count":19,"type":20},"10 Years","Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents. Clinical presentations are multiple, including chest-pain, heart failure and a broad spectrum of arrhythmias. In turn, outcome is largely unpredictable, ranging from mild self-limiting disease, to chronic stage and progressive evolution towards dilated cardiomyopathy, to rapid adverse outcome in fulminant forms. Subsequently, myocarditis is often underdiagnosed and undertreated, and optimal diagnostic and therapeutic strategies are still to be defined. This study, both retrospective and prospective, originally single-center and subsequently upgraded to multicenter, aims at answering multiple questions about myocarditis, with special attention to its arrhythmic manifestations.\n\n1. Optimal diagnostic workflow is still to be defined. In fact, although endomyocardial biopsy (EMB) is still the diagnostic gold standard, especially for aetiology identification, it is an invasive technique. Furthermore, it may lack sensitivity because of sampling errors. By converse, modern imaging techniques - cardiac magnetic resonance (CMR) in particular - have been proposed as alternative or complementary diagnostic tool in inflammatory heart disease. Other noninvasive diagnostic techniques, like delayed-enhanced CT (DECT) scan or position emission tomography (PET) scan, are under investigation.\n2. Biomarkers to identify myocarditis aetiology, predisposition, prognosis and response to treatment are still to be defined.\n3. Arrhythmic myocarditis is largely underdiagnosed and uninvestigated. Importantly, myocarditis presenting with arrhythmias requires specific diagnostic, prognostic and therapeutic considerations. At the group leader hospital, which is an international referral center for ventricular arrhythmias management and ablation, a relevant number of patients with unexplained arrhythmias had myocarditis as underlying aetiology. The experience of a dedicated third-level center is going to be shared with other centers, to considerably improve knowledge and management of arrhythmic myocarditis.\n4. The role of CMR, as well as alternative noninvasive imaging techniques, in defining myocarditis healing is a relevant issue. In particular, optimal timing for follow-up diagnostic reassessment is still to be defined, in patients with myocarditis at different inflammatory stages, either with or without aetiology-dependent treatment.\n5. Uniformly-designed studies are lacking, to compare myocarditis among different patient subgroups, differing by variables like: clinical presentations, myocarditis stage, associated cardiac or extra-cardiac diseases, aetiology-based treatment, associated arrhythmic manifestations, diagnostic workup, and devices or ablation treatment.",[37,71,38,157,158,159,25,198,161],"Immunosuppression",[37,163,164,165,166,167,168,169,200,170,171,172,173,174,175,176,177],"Cardiac imaging","2024-09-07",{"date":180,"type":45},{"date":204,"type":45},"2018-01-30",{"date":206,"type":20},"2035-12-31",{"name":186,"class":52},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":121,"enrollmentInfo":216,"targetDuration":218,"studyType":21,"phases":4,"briefSummary":219,"conditions":220,"keywords":227,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":112},"100382854","dzhk-torch-plus-is-a-registry-for-patients-with-cardiomyopathies-and-serves-as-source-for-cardiovascular-research-studies-100382854","NCT04265040","DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies","TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)","TORCH-Plus","Inclusion Criteria:\n\n* Non-ischemic structural cardiomyopathies\n* Age ≥ 18 or ≤ 80 years\n* The patient is able to understand the declaration of consent and to sign it dated\n* At least one of the following diagnoses depending on the specific TORCH-\n\nPlus inclusion \u002F exclusion - SOP:\n\nDilated Cardiomyopathy (DCM)\n\n* family \u002F genetic\n* inflammatory \u002F persistent myocarditis\n* idiopathic (after exclusion secondary cause)\n* left sided systolic dysfunction (EF ≤ 45%)\n\nLeft ventricular hypertrophy\n\n* sarcomere hypertrophic cardiomoypathia (HCM, HOCM)\n* amyloid (AL: light chains, TTR: transthyretin, wild type)\n\nLeft ventricular non-compaction cardiomyopathy (LVNC)\n\nArrhythmogenic right ventricular cardiomyopathy (ARVC \u002F D)\n\nExclusion Criteria:\n\nThe following exclusion criteria have been defined and must be taken from the TORCH-Plus specific inclusion \u002F exclusion - SOP in detail:\n\n* Age: \\\u003C18 years or\\> 80 years\n* Patient has other (cardiac) previous illnesses:\n\n  * uncontrollable arterial hypertension\n  * primary pulmonary arterial hypertension\n  * radiation therapy in the chest area\n  * addiction (drug or alcohol abuse)\n  * life expectancy \\\u003C1 year due to non-cardiological pre-existing conditions\n  * significant heart valve disease\n  * ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)\n  * chemotoxic cardiomyopathy\n  * condition after myocarditis\n  * combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)\n  * advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)\n  * Tachymyopathy",{"count":217,"type":20},2040,"4 Years","The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity.\n\nThis DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. \"Clinical phenotyping, follow-up \\& biosampling\" 2. \"Genomics\", 3. \"Inflammation\" and 4. \"Biomarker\". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.",[221,222,223,224,24,225,226,38],"Non-ischemic Cardiomyopathy","DCM - Dilated Cardiomyopathy","HCM - Hypertrophic Cardiomyopathy","HOCM - Hypertrophic Obstructive Cardiomyopathy","Left Ventricular Noncompaction Cardiomyopathy","Amyloidosis",[228],"Cardiomyopathies, registry, data, biomaterial, genetics","2023-11-29",{"date":231,"type":45},"2023-11-30",{"date":233,"type":45},"2020-08-18",{"date":235,"type":20},"2027-12",{"name":237,"class":52},"University Hospital Heidelberg"]